Montelino Therapeutics LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor variant 7 (AR-v7)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Centre National de la Recherche Scientifique and Université Paul Sabatier - Toulouse III have divulged alkynylcarbinols acting as 17β -hydroxysteroid dehydrogenase 11 (17β-HSD11; 17bHSD11; 17βHSD11)-activated compounds reported to be useful for the treatment of cancer, bacterial, fungal and parasitic infections.
Ubix Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a protein ENL (MLLT1; YEATS1) targeting moiety via linker.
Shouyao Holdings (Beijing) Co. Ltd. has synthesized DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Astrazeneca has described spirocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Researchers at Dana-Farber Cancer Institute Inc., Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center and Stevens Institute of Technology have divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety linked to cyclin-dependent kinase 4 (CDK4) and/or 6 (CDK6)-targeting moiety through a linker.
Nutshell Biotech (Shanghai) Co. Ltd. has identified fused ring compounds acting as fibroblast growth factor receptor 4 (FGFR4) inhibitors reported to be useful for the treatment of cancer and myeloproliferative diseases.
Medshine Discovery Inc. has synthesized PROTAC compounds comprising an E3 ubiquitin ligase binding moiety coupled to IRAK-4-targeting moiety through a linker.
Shanghai Haihe Biopharma Co. Ltd. has disclosed hydroxamic acid compounds acting as ENPP1 inhibitors reported to be useful for the treatment of cancer and infections.
RSS